{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:33:09Z","timestamp":1790177589150,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.biologicals.2014.05.005","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T16:00:25Z","timestamp":1403366425000},"page":"177-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["The challenge of indication extrapolation for infliximab biosimilars"],"prefix":"10.1016","volume":"42","author":[{"given":"Brian G.","family":"Feagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopi","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Sealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biologicals.2014.05.005_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40259-013-0020-y","article-title":"Development and regulation of biosimilars: current status and future challenges","volume":"27","author":"Tsiftsoglou","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.biologicals.2014.05.005_bib2","series-title":"Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues","author":"Committee for Medicinal Products for Human Use, European Medicines Agency","year":"2012"},{"key":"10.1016\/j.biologicals.2014.05.005_bib3","series-title":"Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs)","author":"Health Products and Food Branch, Health Canada","year":"2010"},{"key":"10.1016\/j.biologicals.2014.05.005_bib4","series-title":"Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft guidance)","author":"U.S. Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.biologicals.2014.05.005_bib5","series-title":"Guidelines on evaluation of similar biotherapeutic products","author":"Expert Committee on Biological Standardization, World Health Organization","year":"2009"},{"key":"10.1016\/j.biologicals.2014.05.005_bib6","series-title":"KFDA approves RemsimaTM (infliximab), the world's first antibody biosimilar","author":"Celltrion, Inc","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib7","series-title":"Remsima: assessment report","author":"Committee for Medicinal Products for Human Use, European Medicines Agency","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib8","series-title":"Inflectra: assessment report","author":"Committee for Medicinal Products for Human Use, European Medicines Agency","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib9","unstructured":"Celltrion Healthcare Co. Ltd. REMSIMA (infliximab) Product Monograph."},{"key":"10.1016\/j.biologicals.2014.05.005_bib10","unstructured":"Celltrion Healthcare Co. Ltd. INFLECTRA (infliximab) Product Monograph."},{"key":"10.1016\/j.biologicals.2014.05.005_bib11","series-title":"REMICADE (infliximab) summary of product characteristics","author":"Janssen Biologics B.V","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib12","series-title":"REMICADE (infliximab) prescribing information","author":"Janssen Biotech, Inc","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib13","series-title":"REMICADE (infliximab) product monograph","author":"Janssen Inc","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib14","series-title":"Remsima summary of opinion (initial authorization)","author":"Committee for Medicinal Products for Human Use, European Medicines Agency","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib15","series-title":"Inflectra summary of opinion (initial authorization)","author":"Committee for Medicinal Products for Human Use, European Medicines Agency","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib16","series-title":"Summary basis of decision \u2013 INFLECTRA","author":"Health Canada","year":"2014"},{"key":"10.1016\/j.biologicals.2014.05.005_bib17","series-title":"Summary basis of decision \u2013 REMSIMA","author":"Health Canada","year":"2014"},{"key":"10.1016\/j.biologicals.2014.05.005_bib18","unstructured":"Celltrion Healthcare. The rise of biosimilar mAbs: the new era of biologic therapy in rheumatology. Satellite Symposium at European League Against Rheumatism (EULAR) Congress. Madrid, Spain. June 6, 2013."},{"issue":"10","key":"10.1016\/j.biologicals.2014.05.005_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A\u00a0randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.biologicals.2014.05.005_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A\u00a0randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.biologicals.2014.05.005_bib21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.crohns.2013.12.002","article-title":"Biosimilars in Crohn's disease","volume":"8","author":"Scheinberg","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1016\/j.biologicals.2014.05.005_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-alpha for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"10.1016\/j.biologicals.2014.05.005_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"issue":"10","key":"10.1016\/j.biologicals.2014.05.005_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1155\/2013\/327120","article-title":"Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics","volume":"27","author":"Devlin","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"10","key":"10.1016\/j.biologicals.2014.05.005_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1155\/2013\/634176","article-title":"Subsequent entry biologics \u2013 opportunities and challenges","volume":"27","author":"Ghosh","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.biologicals.2014.05.005_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.biologicals.2014.05.005_bib27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.20344\/amp.5001","article-title":"Impact of biosimilars in psoriasis treatment","volume":"26","author":"Torres","year":"2013","journal-title":"Acta Med Port"},{"issue":"9","key":"10.1016\/j.biologicals.2014.05.005_bib28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.biologicals.2014.05.005_bib29","series-title":"Study to compare effectiveness and safety of ABP 501 and adalimumab in adults with moderate to severe plaque psoriasis","author":"Amgen","year":"2014"},{"key":"10.1016\/j.biologicals.2014.05.005_bib30","series-title":"Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and Humira (ADACCESS)","author":"Sandoz","year":"2014"},{"issue":"6","key":"10.1016\/j.biologicals.2014.05.005_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family","volume":"76","author":"Gessner","year":"1998","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.biologicals.2014.05.005_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.biologicals.2014.05.005_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd3365","article-title":"Advances in the assessment and control of the effector functions of therapeutic antibodies","volume":"10","author":"Jiang","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.biologicals.2014.05.005_bib34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.7.7.1051","article-title":"Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases","volume":"7","author":"Tilg","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.biologicals.2014.05.005_bib35","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.biologicals.2014.05.005_bib36","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.biologicals.2014.05.005_bib37","series-title":"ENBREL (etanercept) product monograph","author":"Amgen Canada Inc","year":"2013"},{"issue":"5","key":"10.1016\/j.biologicals.2014.05.005_bib38","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biologicals.2014.05.005_bib39","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.biologicals.2014.05.005_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.biologicals.2014.05.005_bib41","series-title":"HUMIRA (adalimumab) product monograph","author":"AbbVie Corporation","year":"2014"},{"issue":"1","key":"10.1016\/j.biologicals.2014.05.005_bib42","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A\u00a0randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.biologicals.2014.05.005_bib43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.biologicals.2014.05.005_bib44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.biologicals.2012.09.010","article-title":"Health Canada\/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012","volume":"40","author":"Kay","year":"2012","journal-title":"Biologicals"},{"issue":"7","key":"10.1016\/j.biologicals.2014.05.005_bib45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.biologicals.2014.05.005_bib46","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.biologicals.2014.05.005_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270008316886","article-title":"Population pharmacokinetics of infliximab in patients with ankylosing spondylitis","volume":"48","author":"Xu","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"Suppl.\u00a074","key":"10.1016\/j.biologicals.2014.05.005_bib48","first-page":"13","article-title":"Clinical pharmacokinetics of tumor necrosis factor antagonists","author":"Nestorov","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"9853","key":"10.1016\/j.biologicals.2014.05.005_bib49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biologicals.2014.05.005_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaut.2012.05.021","article-title":"Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction","volume":"39","author":"Boissier","year":"2012","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.biologicals.2014.05.005_bib51","first-page":"168321","article-title":"Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis","author":"Chong","year":"2013","journal-title":"Biomed Res Int"},{"issue":"4 Suppl.\u00a055","key":"10.1016\/j.biologicals.2014.05.005_bib52","first-page":"S10","article-title":"Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Lories","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.biologicals.2014.05.005_bib53","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2010.140582","article-title":"Psoriatic arthritis: update on pathophysiology, assessment and management","volume":"70","author":"Mease","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9853","key":"10.1016\/j.biologicals.2014.05.005_bib54","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biologicals.2014.05.005_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2012.10.014","article-title":"Tumor necrosis factor","volume":"328","author":"Chu","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.biologicals.2014.05.005_bib56","series-title":"SIMPONI (golimumab) product monograph","author":"Janssen Inc","year":"2013"},{"key":"10.1016\/j.biologicals.2014.05.005_bib57","series-title":"CIMZIA (certolizumab pegol) product monograph","author":"Canada Inc","year":"2014"},{"issue":"4","key":"10.1016\/j.biologicals.2014.05.005_bib58","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.biologicals.2014.05.005_bib59","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105614000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105614000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:13:04Z","timestamp":1760922784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105614000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1045105614000451"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2014.05.005","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of indication extrapolation for infliximab biosimilars","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2014.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}